{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:42:02Z","timestamp":1769082122771,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"DOI":"10.7759\/cureus.102005","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:43:46Z","timestamp":1769021026000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Beta-Thalassemia Trait on Clinical Outcomes and Treatment Response in Chronic Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Aytan","family":"Shirinova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chingiz","family":"Asadov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aypara","family":"Hasanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohra","family":"Alimirzoyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"28","author":"Hehlmann R","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007, 28:342-50. 10.1016\/S0140-6736(07)61165-9","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker BJ","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al.. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344:1031-7. 10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al.. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017, 376:917-27. 10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello R","year":"2010","unstructured":"Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010, 5:10.1186\/1750-1172-5-11","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32835f5a5c","article-title":"Iron overload in \u03b2-thalassemia intermedia: an emerging concern","volume":"20","author":"Musallam KM","year":"2013","unstructured":"Musallam KM, Cappellini MD, Taher AT. Iron overload in \u03b2-thalassemia intermedia: an emerging concern. Curr Opin Hematol. 2013, 20:187-92. 10.1097\/MOH.0b013e32835f5a5c","journal-title":"Curr Opin Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb10482.x","article-title":"Global epidemiology of hemoglobin disorders","volume":"850","author":"Angastiniotis M","year":"1998","unstructured":"Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci. 1998, 850:251-69. 10.1111\/j.1749-6632.1998.tb10482.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/03630269.2024.2427189","article-title":"Update on prevention of hemoglobinopathies in Azerbaijan","volume":"48","author":"Mammadova T","year":"2024","unstructured":"Mammadova T, Asadov C, Alimirzoyeva Z, Abdulalimov E, Aliyeva G. Update on prevention of hemoglobinopathies in Azerbaijan. Hemoglobin. 2024, 48:353-6. 10.1080\/03630269.2024.2427189","journal-title":"Hemoglobin"},{"key":"ref8","article-title":"Thalassemia prevention in Azerbaijan: what have we achieved so far?","volume":"73","author":"Asadov C","year":"2018","unstructured":"Asadov C, Aliyeva G, Mikayilzadeh A, et al.. Thalassemia prevention in Azerbaijan: what have we achieved so far?. Leuk Res. 2018, 73:","journal-title":"Leuk Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251353194","article-title":"Chronic myeloid leukemia in a patient with beta thalassemia major: a rare presentation","volume":"16","author":"Hafeez A","year":"2025","unstructured":"Hafeez A, Shaikh MU, Mallick AH, Nathani N, Alam J. Chronic myeloid leukemia in a patient with beta thalassemia major: a rare presentation. Ther Adv Hematol. 2025, 16:10.1177\/20406207251353194","journal-title":"Ther Adv Hematol"},{"key":"ref10","article-title":"Robbins & Cotran: Pathologic Basis of Disease. Tenth Edition","year":"2020","unstructured":"Robbins & Cotran. Pathologic Basis of Disease. Tenth Edition. Kumar V, Abbas AK, Aster JC (ed): Elsevier, Philadelphia, PA; 2020."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.25080\/Majora-92bf1922-00a","article-title":"Data structures for statistical computing in Python","author":"McKinney W","year":"2010","unstructured":"McKinney W. Data structures for statistical computing in Python. SciPy. 2010, 10.25080\/Majora-92bf1922-00a","journal-title":"SciPy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7342","article-title":"Risk stratification of chronic myeloid leukemia according to different prognostic scores","volume":"12","author":"Aijaz J","year":"2020","unstructured":"Aijaz J, Junaid N, Naveed MA, Maab R. Risk stratification of chronic myeloid leukemia according to different prognostic scores. Cureus. 2020, 12:10.7759\/cureus.7342","journal-title":"Cureus"},{"key":"ref13","unstructured":"Downloading IBM SPSS Statistics 25. (2022). https.\/\/www.ibm.com\/support\/pages\/downloading-ibm-spss-statistics-25."},{"key":"ref14","article-title":"Practical Statistics for Medical Research","year":"1990","unstructured":"Practical Statistics for Medical Research. Ashby DG (ed). Chapman and Hall\/CRC, Boca Raton, FL; 1990."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. JAMA. 2013, 310:2191-4. 10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i29.10655","article-title":"Myeloproliferative neoplasms complicated with \u03b2-thalassemia: two case report","volume":"10","author":"Xu NW","year":"2022","unstructured":"Xu NW, Li LJ. Myeloproliferative neoplasms complicated with \u03b2-thalassemia: two case report. World J Clin Cases. 2022, 10:10655-62. 10.12998\/wjcc.v10.i29.10655","journal-title":"World J Clin Cases"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-018-0373-5","article-title":"Oxidative stress in \u03b2-thalassemia","volume":"23","author":"Fibach E","year":"2019","unstructured":"Fibach E, Dana M. Oxidative stress in \u03b2-thalassemia. Mol Diagn Ther. 2019, 23:245-61. 10.1007\/s40291-018-0373-5","journal-title":"Mol Diagn Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-thalassemias","volume":"384","author":"Taher AT","year":"2021","unstructured":"Taher AT, Musallam KM, Cappellini MD. \u03b2-thalassemias. N Engl J Med. 2021, 384:727-43. 10.1056\/NEJMra2021838","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2013.08.005","article-title":"Hypoxia and HIFs in regulating the development of the hematopoietic system","volume":"51","author":"Imanirad P","year":"2013","unstructured":"Imanirad P, Dzierzak E. Hypoxia and HIFs in regulating the development of the hematopoietic system. Blood Cells Mol Dis. 2013, 51:256-63. 10.1016\/j.bcmd.2013.08.005","journal-title":"Blood Cells Mol Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2471\/blt.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell B","year":"2008","unstructured":"Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008, 86:480-7. 10.2471\/blt.06.036673","journal-title":"Bull World Health Organ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot F","year":"2017","unstructured":"Millot F, Guilhot J, Suttorp M, et al.. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica. 2017, 102:1704-8. 10.3324\/haematol.2017.170035","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults","volume":"14","author":"Petain A","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, et al.. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008, 14:7102-9. 10.1158\/1078-0432.CCR-08-0950","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050436","article-title":"\u03b2-thalassemia","volume":"353","author":"Rund D","year":"2005","unstructured":"Rund D, Rachmilewitz E. \u03b2-thalassemia. N Engl J Med. 2005, 353:1135-46. 10.1056\/NEJMra050436","journal-title":"N Engl J Med"},{"key":"ref24","article-title":"GeneReviews [Internet]","year":"2024","unstructured":"GeneReviews [Internet]. Adam MP, Bick S, Mirzaa GM, et al. (ed). University of Washington, Seattle, WA; 2024."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2009.006","article-title":"Iron metabolism in thalassemia and sickle cell disease","volume":"1","author":"Mariani R","year":"2009","unstructured":"Mariani R, Trombini P, Pozzi M, Piperno A. Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis. 2009, 1:10.4084\/MJHID.2009.006","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.1.36","article-title":"The hypercoagulable state in thalassemia","volume":"99","author":"Eldor A","year":"2002","unstructured":"Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002, 99:36-43. 10.1182\/blood.v99.1.36","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452721-impact-of-beta-thalassemia-trait-on-clinical-outcomes-and-treatment-response-in-chronic-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:43:47Z","timestamp":1769021027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452721-impact-of-beta-thalassemia-trait-on-clinical-outcomes-and-treatment-response-in-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.102005","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}